Anne-Laure Voisin

Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease

François‐Xavier Danlos, Anne-Laure Voisin, Valérie Dyevre et al. · European Journal of Cancer · 2018 · 311 citations

Life Sciences, Immunology, Oncology +16

Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study

Nicolas Delanoy, Jean‐Marie Michot, Thibault Comont et al. · The Lancet Haematology · 2018 · 292 citations

Pharmacy, Hematology, Immunology +16

Rheumatoid arthritis and polymyalgia rheumatica occurring after immune checkpoint inhibitor treatment

Rakiba Belkhir, S. Le Burel, Laetitia Dunogeant et al. · Annals of the Rheumatic Diseases · 2017 · 242 citations

Life Sciences, Immunology, Pharmacotherapy +17

Prevalence of immune-related systemic adverse events in patients treated with anti-Programmed cell Death 1/anti-Programmed cell Death-Ligand 1 agents: A single-centre pharmacovigilance database analysis

S. Le Burel, Stéphane Champiat, Christine Mateus et al. · European Journal of Cancer · 2017 · 199 citations

Pharmacy, Pharmacology, Pharmacotherapy +13

Inflammatory gastrointestinal diseases associated with PD-1 blockade antibodies

Michael Collins, Jean‐Marie Michot, F.X. Danlos et al. · Annals of Oncology · 2017 · 154 citations · Full text

Life Sciences, Immunology, Internal Medicine +14